These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 6976062

  • 1. In vitro cytotoxicity of lymphocyte subpopulations against autologous human bladder tumor cells.
    Jacobsen F.
    Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):241-6. PubMed ID: 6976062
    [Abstract] [Full Text] [Related]

  • 2. Significance of cytotoxic activity of peripheral blood lymphocytes against autologous tumor cells in patients with bladder cancer.
    Mizutani Y, Okada Y, Yoshida O, Bonavida B.
    Cancer Biother Radiopharm; 1996 Dec; 11(6):385-91. PubMed ID: 10851499
    [Abstract] [Full Text] [Related]

  • 3. Lymphocyte cytotoxicity against autologous bladder tumor cells in humans, investigated by use of a chromium-51 release assay.
    Jacobsen F.
    Acta Pathol Microbiol Scand C; 1981 Jun; 89(3):175-80. PubMed ID: 7315355
    [Abstract] [Full Text] [Related]

  • 4. Activation by the protein-bound polysaccharide PSK (krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in patients with urinary bladder cancer.
    Mizutani Y, Yoshida O.
    J Urol; 1991 May; 145(5):1082-7. PubMed ID: 2016797
    [Abstract] [Full Text] [Related]

  • 5. Cellular and humoral in vitro cytotoxicity against autologous bladder tumor cells in humans. Differences in autologous cytotoxicity against non-invasive and invasive transitional-cell tumors of the urinary bladder.
    Jacobsen F.
    Acta Pathol Microbiol Scand C; 1981 Aug; 89(4):235-9. PubMed ID: 7315359
    [Abstract] [Full Text] [Related]

  • 6. Transitional cell carcinoma: lymphocyte-mediated cytotoxicity.
    Troye M, Pape GR.
    Natl Cancer Inst Monogr; 1978 Dec; (49):85-7. PubMed ID: 311895
    [Abstract] [Full Text] [Related]

  • 7. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.
    Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M.
    J Exp Med; 1987 Aug 01; 166(2):303-18. PubMed ID: 2955070
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxicity in vitro of blood lymphocytes from bladder cancer patients and controls to allogeneic or autologous tumor cells derived from established cell lines or short-term cultures.
    Troye M, Vilien M, Pape GR, Perlmann P.
    Int J Cancer; 1980 Jan 15; 25(1):33-43. PubMed ID: 7399743
    [Abstract] [Full Text] [Related]

  • 9. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y, Yoshida O, Bonavida B.
    J Urol; 1998 Aug 15; 160(2):571-6. PubMed ID: 9679930
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y, Okada Y, Terachi T, Yoshida O.
    J Urol; 1996 Mar 15; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dendritic cell transfected with secondary lymphoid-tissue chemokine and/or interleukin-2 gene-enhanced cytotoxicity of T-lymphocyte in human bladder tumor cell S in vitro.
    Li YG, Wang ZP, Tian JQ, Tian BQ, Rodrigues R, Shang PF, Zhang T.
    Cancer Invest; 2009 Nov 15; 27(9):909-17. PubMed ID: 19832038
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Cellular immune response of bladder tumor patients: effects of aging on cytotoxic activity against T24].
    Kato M.
    Hinyokika Kiyo; 1988 Aug 15; 34(8):1363-9. PubMed ID: 3195404
    [Abstract] [Full Text] [Related]

  • 17. Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte-mediated cytotoxicity.
    Vánky FT, Vose BM, Fopp M, Klein E.
    J Natl Cancer Inst; 1979 Jun 15; 62(6):1407-13. PubMed ID: 86634
    [Abstract] [Full Text] [Related]

  • 18. Depression of the generation of cell-mediated cytotoxicity by macrophage-like suppressor cells in bladder carcinoma patients.
    Spina CA, Dorey F, Vescera C, Brosman S, Fahey JL.
    Cancer Res; 1981 Nov 15; 41(11 Pt 1):4324-30. PubMed ID: 6458353
    [Abstract] [Full Text] [Related]

  • 19. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.
    Cancer; 1994 Aug 15; 74(4):1275-82. PubMed ID: 7914469
    [Abstract] [Full Text] [Related]

  • 20. MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomas.
    Housseau F, Zeliszewski D, Roy M, Paradis V, Richon S, Ricour A, Bougaran J, Prapotnich D, Vallancien G, Benoit G, Desportes L, Bedossa P, Hercend T, Bidart JM, Bellet D.
    Int J Cancer; 1997 May 16; 71(4):585-94. PubMed ID: 9178812
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.